Tinzaparin: Considerations for Use in Clinical Practice

Annals of Pharmacotherapy

Volumn 37, Issue 12, 2003, Pages 1831-1840

  Nutescu, Edith A ^a   Shapiro, Nancy L ^a   Feinstein, Helen ^a   Rivers, Christina W ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Edward Hines Jr Vet Aff Med Ctr   (United States)

Author keywords

Anticoagulants; Antithrombotic agents; Low molecular weight heparin; Tinzaparin

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTAMINE SULFATE; PROTHROMBIN; PROTHROMBIN A; THROMBOPLASTIN; TINZAPARIN; WARFARIN;

ABDOMINAL SURGERY; ANGINA PECTORIS; ANTICOAGULATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; COMPRESSION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEEP VEIN THROMBOSIS; DEPOLYMERIZATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG STABILITY; DRUG USE; DRUG WITHDRAWAL; EPIDURAL HEMATOMA; EPITHELIUM; FEASIBILITY STUDY; GENERAL SURGERY; GERIATRIC PATIENT; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HIP ARTHROPLASTY; HUMAN; IMMOBILIZATION; KIDNEY DISEASE; LUNG EMBOLISM; MEDLINE; MOBILIZATION; OBESITY; ORTHOPEDIC SURGERY; OUTPATIENT; PARALYSIS; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN SECRETION; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; THROMBOEMBOLISM; THROMBOSIS; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

ANIMALS; CLINICAL TRIALS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; VENOUS THROMBOSIS;

EID: 0344844499     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D221     Document Type: Review

References (56)

1. Package insert. Fragmin (dalteparin sodium injection). Kalamazoo, MI: Pharmacia and Upjohn, March 2003.
2. Package insert. Lovenox (enoxaparin sodium injection). Bridgewater, NJ: Aventis Pharmaceuticals Products, January 2003.
3. Package insert. Innohep (tinzaparin sodium injection). Boulder, CO: Pharmion, January 2003.
4. Weitz JI. Drug therapy: low molecular weight heparin. N Engl J Med 1997;337:688-98.
5. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
6. Fareed J, Haas S, Sasahara A, eds. Differentiation of low molecular weight heparins: applied and clinical considerations. Semin Thromb Hemost 1999;25(suppl 3):3-4.
7. Martineau P, Tawil N. Low-molecular-weight heparins in the treatment of deep vein thrombosis. Ann Pharmacother 1998;32:588-98,601.
8. Norrheim L, Abildgaard U, Larsen ML, Lindahl AK. Involvement of the extrinsic pathway in the activities of low molecular weight heparins. Thromb Res 1991;14(suppl):19-27.
9. Leizorovicz A, Bara L, Samama MM, Haugh MC. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and hemorrhage. Haemostasis 1993;23(suppl 1):89-98.
10. Bara L, Leizorovicz A, Picolet H, Samama M. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Thromb Res 1992;65:641-50.
11. Kijowski R, Hoppensteadt D, Walenga J, Boris L, Rud Lassen M, Fareed J. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin. Thromb Res 1994;74:53-64.
12. Os0tergaard P, Nordfang O, Petersen LC, Valentin S, Kristensen H. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations. Haemostasis 1993;23(suppl 1):107-11.
13. Mousa SA, Bozarth J, Barrett JS. Pharmacodynamic properties of the low-molecular-weight heparin, tinzaparin. The effects of molecular weight fractions on the release of plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol 2003;43(7):727-34.
14. Hull RD, Raskob MB, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975-82.
15. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J-P, Azarian R, et al., for the THESEE Study Group. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-9.
16. Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, et al., for the American-Canadian Thrombosis Study Group. Low-molecular-weight heparin vs. heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000;160:229-36.
17. Siegbahn A, Y-Hassan S, Boberg J, Bylund H, Neerstrand HS, Ostergaard P, et al. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo. Thromb Res 1989;55:767-78.
18. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998;158:2001-3.
19. Lapidus L, Borretzen J, Gronlund Thomsen H, Fahlen M, Hasselblom S, Larson L, et al. Home treatment of deep-vein thrombosis - an out-patient model with once daily injection of LMWH (Innohep) in graduated syringes (abstract). Haemostasis 2000;30(suppl 1):7-8.
20. Wells PS, Rodger M, Forgie M, Anderson D, Kovacs M, Florack P, et al. A randomised trial comparing two low molecular weight heparins (LMWHs) for the outpatient treatment of DVT or PE (abstract OC968). Presented at: International Society on Thrombosis and Haemostasis XVIII Congress, Paris, July 6-12, 2001.
21. Pineo GF on behalf of the LITE Study Investigators. HOME-LITE: Safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal venous thrombosis using subcutaneous low-molecular-weight heparin versus warfarin (abstract OC1647). Presented at: International Society on Thrombosis and Haemostasis XVIII Congress, Paris, July 6-12, 2001.
22. Hull RD, Pineo GF, Mah AF, for the LITE study investigators. Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the posttreatment period for patients randomized to long-term low-molecular-weight heparin (LMWH) vs. warfarin sodium (abstract). Blood 2002;100:501A.
23. Lassen MR, Borris LC, Christiansen HM, Boll KL, Eiskjaer SP, Nielsen BW, et al. Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. Acta Orthorop Scand 1991;62:33-8.
24. Lassen MR, Borris LC, Jensen HP, Poulsen KA, Ejstrud P, Andersen BS. Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty. Clin Appl Thromb Hemost 2000;6:53-7.
25. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, et al. A comparison of subcutaneous low-molecular-weight-heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-6.
26. Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle N, et al. Prevention of deep vein thrombosis after hip replacement. Comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 1999;81:22-5.
27. Planes A. An equivalence study of two low-molecular-weight heparins in the prevention and treatment of deep-vein thrombosis after total hip replacement. Semin Thromb Hemost 2000;26(suppl 1):57-60.
28. Hauch O, Jorgensen LN, Kolle TR, Nerstrom H, Schebye O, Wille-Jorgensen P, et al. Low molecular weight heparin (Logiparin) as thromboprophylaxis in elective abdominal surgery. A dose-finding study. Acta Chir Scand Suppl 1988;543:90-5.
29. Liezorovicz A, Picolet H, Peyrieux JC, Boissel JP, and the H.B.P.M. Research Group. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg 1991;78:412-6.
30. Bergqvist D, Flordal PA, Friberg B, Frisell J, Hedberg M, Liungstrom KG, et al. Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. Vasa 1996;25:156-60.
31. Lausen I, Jensen R, Jorgensen LN, Rasmussen MS, Lyng KM, Andersen M, et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg 1998;164:657-63.
32. Green D, Yee MY, Lim AC, Chmiel JS, Vetter M, Pang T, et al. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med 1990;113:571-4.
33. Jorgensen PS, Warming T, Hansen K, Paltved C, Berg HV, Jensen R, et al. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast. A venografic controlled study. Thromb Res 2002;105:477-80.
34. Suvarna TT, Parikh JA, Keshav R, Pillai MG, Pahlajani DB, Gandhi MJ. Comparison of clinical outcome of fixed-dose subcutaneous low molecular weight heparin (tinzaparin) with conventional heparin in unstable angina: a pilot study. Indian Heart J 1997;49:159-62.
35. Michalis LK, Papamichail N, Katsouras CS, Karahaliou A, Souria E, Novas J, et al. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET study) (abstract). J Am Coll Cardiol 2001;37(suppl A):365A.
36. Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001;358:702-10.
37. Siguret V, Pautas E, Fevrier M, Wipff C, Durand-Gasselin B, Laurent M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-II a activities over 10 days. Thromb Haemost 2000;84:800-4.
38. Pautas E, Gourin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002;25:725-33.
39. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 2001;21:218-34.
40. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998;122:799-807.
41. Ryan KE, Lane DA, Flynn A, Shepperd J, Ireland HA, Curtis JR. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis. Thromb Haemost 1991;66:277-82.
42. Simpson HK, Baird J, Allison M, Briggs JD, Rowe PA, Welsh M, et al. Long-term use of the low molecular weight heparin tinzaparin in haemodialysis. Haemostasis 1996;26:90-7.
43. Egfjord M, Rosenlund L, Hedegaard B, Lovdahl Buchardt H, Stengel C, Gardar P, et al. Dose titration study of tinzaparin, a low molecular weight heparin, in patients on chronic hemodialysis. Artif Organs 1998;22:633-7.
44. Hainer JW, Barrett JS, Assaid CA, Fossler MJ, Cos DS, Leathers T, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 2002;87:817-23.
45. Smith MP, Norris LA, Stanley JL, Viscomi L, Steer PJ, Bonnar J, et al. Innohep in pregnancy: a dose finding study of subcutaneous tinzaparin for thrombosis treatment and prevention during pregnancy (abstract 2792). Presented at: American Society of Hematology meeting, San Francisco, December 1-5, 2000.
46. Dalsgaard J. Treatment of venous thromboembolism with tinzaparin during pregnancy (abstract). Ann Hematol 1999;78(suppl):A3.
47. Ellison J, Thomson AJ, Conkie JA, McCall F, Walker ID, Greer IA. Thromboprophylaxis following caesarean section - a comparison of the antithrombotic properties of three low molecular weight heparins - dalteparin, enoxaparin and tinzaparin. Thromb Haemost 2001;86:1374-8.
48. Bonnar J. Can more be done in obstetric and gynecologic practice to reduced morbidity and mortality associated with venous thromboembolism? Am J Obstet Gynecol 1999;180:784-91.
49. Hull RD, Raskob GE, Rosenbloom D, Pineo GF, Lerner RG, Gafni A, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs. intravenous heparin: an economic perspective. Arch Intern Med 1997;157:289-94.
50. Hoffmeyer U, Lewis D, Minhas N, Prabhu V, Monk D, Hogan B. Economic evaluation of the use of Innohep in the treatment of acute pulmonary embolism. J Med Econ 1998;1:148-62.
51. Valette F, Hoffmeyer U, Lloyd A. Economic evaluation of the use of tinzaparin in the treatment of deep vein thrombosis. Br J Med Econ 1995;8:111-23.
52. Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis 1998;28(suppl 3):8-16.
53. Caro JJ, Getsios D, Caro I, O'Brien JA. Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. Pharmacoeconomics 2002;20:593-602.
54. Wade WE, Spruill WJ. Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis in spinal cord injury: preliminary data. Blood Coag Fibrinolysis 2001;12:619-25.
55. Turner KA, Haines ST, Polli JE. Activity of tinzaparin sodium in extemporaneously prepared syringes. Presented at: American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 2-7, 2000.
56. Holst J, Lindblad B, Bergqvist D, Garre K, Nielsen H, Hedner U, et al. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers. Blood Coag Fibrinolysis 1994;5:795-803.